Posted by Michael Wonder on 27 Feb 2023
SpringWorks Therapeutics announces FDA acceptance and priority review of new drug application for nirogacestat for the treatment of adults with desmoid tumours
27 February 2023 - PDUFA action date set for 27 August 2023.
SpringWorks Therapeutics announced today that the US FDA has accepted the Company’s new drug application for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumours.
